People: Impax Laboratories Inc (IPXL.O)

Summary

Name	Age	Since	Current Position
Robert Burr	61		Independent Chairman of the Board
Larry Hsu	63	2006	President, Chief Executive Officer, Director
Bryan Reasons	45	2012	Chief Financial Officer, Senior Vice President - Finance
Carole Ben-Maimon	53	2011	President - Global Pharmaceuticals Division
Michael Nestor	59	2008	President - Impax Pharmaceutical Division
Mark Schlossberg	51	2011	Senior Vice President, General Counsel, Corporate Secretary
Leslie Benet	74	2001	Independent Director
Allen Chao	66	2010	Independent Director
Nigel Fleming		1999	Independent Director
Michael Markbreiter	50	1997	Independent Director
Peter Terreri	54	2003	Independent Director

» Insider Trading

Biographies

Name	Description
Robert Burr	Mr. Robert L. Burr is Independent Chairman of the Board of Impax Laboratories Inc. He has been a self-employed investment manager since May 2008. Mr. Burr was employed by J.P. Morgan Chase & Co. and associated entities from 1995 to May 2008, at which time he resigned his position as Managing Partner of the Fleming US Discovery III Funds. From October 2001 to October 2005, Mr. Burr was also a Partner at Windcrest Discovery Investments LLC, an investment management firm. Mr. Burr previously served as a director of Hudson Technologies, Inc., a publicly traded refrigerant services company, from 1999 to 2007. From 1992 to 1995, Mr. Burr was head of Private Equity at the investment banking firm Kidder, Peabody & Co., Inc. Prior to that time, Mr. Burr served as the Managing General Partner of Morgan Stanley Ventures and General Partner of Morgan Stanley Venture Capital Fund I, L.P. and was a corporate lending officer with Citibank, N.A. Mr. Burr received an MBA from Columbia University and a BA from Stanford University.
Larry Hsu	Dr. Larry Hsu, Ph.D. is President, Chief Executive Officer, Director of Impax Laboratories Inc. He has been the company President and Chief Executive Officer since October 2006. Prior to holding these positions, Dr. Hsu served as the company President and Chief Operating Officer beginning in 1999. Dr. Hsu co-founded Impax Pharmaceuticals, Inc. in 1994 and served as its President, Chief Operating Officer and a member of the board from its inception until its merger with the company in in 1999. From 1980 to 1995, Dr. Hsu worked at Abbott Laboratories, where, during his last four years, he served as Director of Product Development. Dr. Hsu obtained his Ph.D. in pharmaceutics from the University of Michigan. Dr. Hsu’s experience as the company co-founder, President and Chief Executive Officer, and previously the company President and Chief Operating Officer, provides the board with unique insights into the company operations, challenges and opportunities.
Bryan Reasons	Mr. Bryan M. Reasons is the Chief Financial Officer, Senior Vice President - Finance of Impax Laboratories, Inc. He joined the Company in January 2012 as the Company’s Vice President, Finance, and has served as the Company’s Acting Chief Financial Officer since June 2012. He previously served as Vice President, Finance, from January 2010 to November 2011 and as Vice President, Risk Management and General Auditor, from October 2005 to January 2010 at Cephalon, Inc. (“Cephalon”), a biopharmaceutical company. Following the acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. (“Teva”), a generic pharmaceuticals company, he served as the Vice President, Finance, of Teva from November 2011 to January 2012. Prior to joining Cephalon, Mr. Reasons held various finance management positions at Dupont from 2003 to 2005 and served as senior manager at PricewaterhouseCoopers LLP from 1992 to 2003. Mr. Reasons earned a bachelor’s degree in accounting from Pennsylvania State University and an M.B.A. from Widener University and is a certified public accountant.
Carole Ben-Maimon	Dr. Carole S. Ben-Maimon, M.D., is President - Global Pharmaceuticals Division of Impax Laboratories, Inc., since September 6, 2011. Prior to joining the Company, she served as Senior Vice President, Corporate Strategy at Qualitest Pharmaceuticals, Inc. from July 2009 to July 2010. Prior to her role at Qualitest, she served as Founder, President and Chief Executive Officer and director of Alita Pharmaceuticals, Inc., an early stage, privately held specialty pharmaceutical company, from September 2006 to June 2009. Dr. Ben-Maimon also held executive positions with and served as a member of the board with Barr Pharmaceuticals from 2001 to 2006, including as president and chief operating officer of Duramed Research, Inc. (a wholly owned subsidiary of Barr Pharmaceuticals Inc.). Dr. Ben-Maimon also held executive positions with Teva Pharmaceuticals USA where she served as Senior Vice President, Science and Public Policy from 2000 to 2001, Senior Vice President, Research and Development from 1996 to 2000 and Vice President, Medical and Regulatory Affairs with Lemmon Company, a wholly owned subsidiary of Teva Pharmaceuticals, Inc. from 1993 to 1996. She served as the Chairman of the Board of the Generic Pharmaceutical Association from 1999 to 2002, and is also a published author of numerous scientific and clinical articles. Dr. Ben-Maimon is a graduate of Thomas Jefferson Medical College and received a Bachelor of Arts in biology from The University of Pennsylvania where she graduated magna cum laude. She is board certified in internal medicine, and completed clinical and research training in nephrology at Thomas Jefferson University.
Michael Nestor	Mr. Michael J. Nestor is President - Impax Pharmaceutical Division of Impax Laboratories Inc. Before joining the company, he was Chief Operating Officer of Piedmont Pharmaceuticals, a specialty pharmaceutical company, from July 2007 to March 2008. Prior to Piedmont, Mr. Nestor was CEO of NanoBio, a startup biopharmaceutical company from December 2004 to November 2006, prior to which he was employed by Alpharma, initially as President of its generic pharmaceutical business and later as President of its branded pharmaceutical business. Before Alpharma, he was President, International business at Banner Inc., a global contract manufacturing concern. Prior to Banner, Mr. Nestor spent 16 years at Lederle Laboratories / Wyeth holding increasing positions of responsibility including Vice President, Cardiovascular business, Vice President / General Manager of Lederle-Praxis Biologics, and Vice President of Wyeth-Lederle Vaccines and Pediatrics. Mr. Nestor has a Bachelor of Business Administration degree from Middle Tennessee State University and a MBA from Pepperdine University.
Mark Schlossberg	Mr. Mark A. Schlossberg is Senior Vice President, General Counsel, Corporate Secretary of Impax Laboratories Inc. Prior to joining the Company, he served as Vice President, Associate General Counsel of Amgen Inc. from September 2004 to May 2011. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc., and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. He earned a Bachelor of Sciences in business administration and finance from the University of Southern California and a Juris Doctor degree from Emory University.
Leslie Benet	Dr. Leslie Z. Benet, Ph.D. is Independent Director of Impax Laboratories Inc. He has been a Professor since 1969 of, and has also served as Chairman of, the Department of Bioengineering and Therapeutic Sciences (1978-1998), University of California, San Francisco (UCSF). Dr. Benet has been a founder of four biopharmaceutical start up companies, for two of which he presently serves on the Scientific Advisory Boards, Limerick Biopharma and Hurel Corp. He received his A.B. (English), B.S. (Pharmacy), and M.S. from the University of Michigan, and his Ph.D. from the University of California. Dr. Benet has received seven honorary doctorates: Uppsala University, Sweden (Pharm.D., 1987); Leiden University, The Netherlands (Ph.D., 1995); University of Illinois at Chicago (D.Sc., 1997); Philadelphia College of Pharmacy and Science (D.Sc., 1997); Long Island University (D.Sc., 1999); University of Athens, Greece (Ph.D., 2005); and Catholic University of Leuven, Belgium (Ph.D., 2010). Dr. Benet’s research interests, more than 500 publications, and 11 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery, and pharmacodynamics. He is listed among the most cited pharmacologists worldwide. In 1985, Dr. Benet served as President of the APhA Academy of Pharmaceutical Sciences. During 1986, Dr. Benet was a founder and first President of the American Association of Pharmaceutical Scientists (AAPS). In 1987, Dr. Benet was elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences (NAS). Dr. Benet has received the highest scientific awards of AAPS (1989 and 2000), Rho Chi (1990), American Association of Colleges of Pharmacy (1991), American Society for Clinical Pharmacology and Therapeutics (1995 and 2010), American Pharmaceutical Association (2000), International Pharmaceutical Federation (2001) and in 2004 received the Pharmaceutical Sciences World Congress Research Achievement Award and the Controlled Release Society Career Achievement in Oral Drug Delivery Award.
Allen Chao	Dr. Allen Chao, Ph.D., is Independent Director of Impax Laboratories Inc. He has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company, since January 2008. Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973. In May of 2000, he received the degree of Doctor of Science from Purdue.
Nigel Fleming	Dr. Nigel Ten Fleming, Ph.D. is Independent Director of Impax Laboratories Inc. He has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company, since January 2008. Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973.
Michael Markbreiter	Mr. Michael Markbreiter is Independent Director of Impax Laboratories Inc. He is a private investor, was a portfolio manager for Morgan Stanley from October 2004 to May 2005 and Sofaer Capital, a global hedge fund, from December 2000 to September 2001. From August 1995 to December 1998, Mr. Markbreiter was a portfolio manager for private equity investments for Kingdon Capital Management Corp., a New York hedge fund. In April 1994, he co-founded Ram Investment Corp., a venture capital company. From March 1993 to January 1994, Mr. Markbreiter was an analyst at Alliance Capital Management Corp. From July 1983 to September 1989, Mr. Markbreiter was an Executive Editor for Arts of Asia magazine. Mr. Markbreiter graduated from Cambridge University with a degree in Engineering.
Peter Terreri	Mr. Peter R. Terreri CPA., is Independent Director of Impax Laboratories Inc. He is President, Chief Executive Officer and director of CGM, Inc., a manufacturing company that he has owned and operated since 2000. He previously served as Senior Vice President and Chief Financial Officer of Teva Pharmaceuticals USA from 1985 through 2000 and as an auditor at PricewaterhouseCoopers LLP from 1981 to 1984. Mr. Terreri received his B.S. in Accounting from Drexel University and has been a certified public accountant since 1981. Mr. Terreri’s more than 20 years of experience in the pharmaceutical industry provides the board with comprehensive understanding of the company operations and strategy.

Basic Compensation

Name	Fiscal Year Total
Robert Burr	--
Larry Hsu	4,348,020
Bryan Reasons	--
Carole Ben-Maimon	1,484,800
Michael Nestor	1,616,850
Mark Schlossberg	2,532,280
Leslie Benet	--
Allen Chao	--
Nigel Fleming	--
Michael Markbreiter	--
Peter Terreri	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Robert Burr	0	0
Larry Hsu	608,580	7,196,780
Bryan Reasons	0	0
Carole Ben-Maimon	0	0
Michael Nestor	7,500	56,625
Mark Schlossberg	0	0
Leslie Benet	0	0
Allen Chao	0	0
Nigel Fleming	0	0
Michael Markbreiter	0	0
Peter Terreri	0	0

Insider Trading

Name	Shares Traded	Price
TERRERI PETER R	666	$17.44
NESTOR MICHAEL J	1,193	$17.00
HSU LARRY CHUNG CHIANG	6,001	$17.00
BURR ROBERT L	1,500	$16.35
TERRERI PETER R	7,500	$8.00
TERRERI PETER R	3,450	$17.39
REASONS BRYAN M	1,159	$16.46
BURR ROBERT L	1,500	$15.97
BURR ROBERT L	7,500	$8.00
FLEMING NIGEL TEN	6,000	$6.55
FLEMING NIGEL TEN	6,000	$16.20
FLEMING NIGEL TEN	6,000	$15.31
FLEMING NIGEL TEN	6,000	$6.55
FLEMING NIGEL TEN	6,000	$6.55
FLEMING NIGEL TEN	6,000	$15.60
BURR ROBERT L	1,500	$16.69
HSU LARRY CHUNG CHIANG	7,000	$16.88
BENET LESLIE Z	500	$16.72
SCHLOSSBERG MARK A	1,000	$16.73
BURR ROBERT L	1,500	$19.82
HSU LARRY CHUNG CHIANG	1,010	$19.99
HSU LARRY CHUNG CHIANG	75,000	$3.04
TERRERI PETER R	12,000	$4.30
BURR ROBERT L	1,500	$21.65
TERRERI PETER R	2,500	$20.95

» Full list on Insider Trading

People: Impax Laboratories Inc (IPXL.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: